339 related articles for article (PubMed ID: 27217465)
21. Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis.
Rozmus J; Kariminia A; Abdossamadi S; Storer BE; Martin PJ; Lee SJ; Wolff D; Arora M; Cutler C; Schultz KR
Biol Blood Marrow Transplant; 2019 Mar; 25(3):451-458. PubMed ID: 30447393
[TBL] [Abstract][Full Text] [Related]
22. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
23. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
24. Global Metabolomics in Allogeneic Hematopoietic Cell Transplantation Recipients Discordant for Chronic Graft-versus-Host Disease.
Lynch Kelly D; Farhadfar N; Starkweather A; Garrett TJ; Yao Y; Wingard JR; Mahmud I; Menzies V; Patel P; Alabasi KM; Lyon D
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1803-1810. PubMed ID: 32592859
[TBL] [Abstract][Full Text] [Related]
25. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.
Kuzmina Z; Krenn K; Petkov V; Körmöczi U; Weigl R; Rottal A; Kalhs P; Mitterbauer M; Ponhold L; Dekan G; Greinix HT; Pickl WF
Blood; 2013 Mar; 121(10):1886-95. PubMed ID: 23303823
[TBL] [Abstract][Full Text] [Related]
26. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
[TBL] [Abstract][Full Text] [Related]
27. The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation.
Weissinger EM; Human C; Metzger J; Hambach L; Wolf D; Greinix HT; Dickinson AM; Mullen W; Jonigk D; Kuzmina Z; Kreipe H; Schweier P; Böhm O; Türüchanow I; Ihlenburg-Schwarz D; Raad J; Durban A; Schiemann M; Könecke C; Diedrich H; Holler E; Beutel G; Krauter J; Ganser A; Stadler M
Leukemia; 2017 Mar; 31(3):654-662. PubMed ID: 27677743
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
[TBL] [Abstract][Full Text] [Related]
29. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
Hartwell MJ; Özbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Wölfl M; Mielke S; Pawarode A; Chen YB; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kröger N; Locatelli F; Morales G; Nakamura R; Reshef R; Rösler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JL
JCI Insight; 2017 Feb; 2(3):e89798. PubMed ID: 28194439
[No Abstract] [Full Text] [Related]
30. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
[TBL] [Abstract][Full Text] [Related]
31. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.
Nakasone H; Tian L; Sahaf B; Kawase T; Schoenrock K; Perloff S; Ryan CE; Paul J; Popli R; Wu F; Otani JM; Coller J; Warren EH; Miklos DB
Blood; 2015 May; 125(20):3193-201. PubMed ID: 25766725
[TBL] [Abstract][Full Text] [Related]
33. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers in chronic graft-versus-host disease: quo vadis?
Wolff D; Greinix H; Lee SJ; Gooley T; Paczesny S; Pavletic S; Hakim F; Malard F; Jagasia M; Lawitschka A; Hansen JA; Pulanic D; Holler E; Dickinson A; Weissinger E; Edinger M; Sarantopoulos S; Schultz KR
Bone Marrow Transplant; 2018 Jul; 53(7):832-837. PubMed ID: 29367715
[TBL] [Abstract][Full Text] [Related]
35. [The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease].
Chen T; Li XP; Zhang C; Kong PY; Gao QG; Tang L; Wang R; Yang SJ; Gao L; Liu Y; Gao L; Feng YM; Rao J; Peng XG; Zhang X
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):948-952. PubMed ID: 31856446
[No Abstract] [Full Text] [Related]
36. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
37. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.
Dai H; Rachakonda SP; Penack O; Blau IW; Blau O; Radujkovic A; Müller-Tidow C; Dreger P; Kumar R; Luft T
Blood Cancer J; 2021 Feb; 11(2):42. PubMed ID: 33640906
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease.
Lai P; Weng J; Lu Z; Guo R; Luo C; Wu S; Ling W; Geng S; Du X
DNA Cell Biol; 2011 Dec; 30(12):1019-25. PubMed ID: 21682596
[TBL] [Abstract][Full Text] [Related]
40. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
